{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:02:04Z","timestamp":1775800924763,"version":"3.50.1"},"reference-count":39,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Little is known about the impact of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) on brain atrophy. This multicenter longitudinal study compares brain MRI volumes and T2 lesion volume between MOGAD patients, relapsing-remitting MS (RRMS) patients and a healthy control (HC) group with brain MRI scans available from an online repository. Methods: In total, 16 adult MOGAD patients (9 F) were age- and sex-matched with 44 RRMS patients (17 F) recruited in Verona MS Center and 14 HC subjects. The availability of two brain MRI scans performed 18 \u00b1 6 months apart was mandatory for each patient. Annual percentage brain volume change (PBVC\/y), baseline global brain, white matter (WM), gray matter (GM) regional brain volumes and T2 lesion volume were compared between groups. Results: PBVC\/y was lower in MOGAD than in RRMS patients (p = 0.014) and lower in HC subjects than in MS patients (p = 0.005). Overall, MOGAD showed higher mean global brain (p = 0.012) and WM volume (p = 0.024) but lower median T2 lesion volume at timepoint 1 (p &lt; 0.001); T2 lesion volume increased over time in the RRMS (p &lt; 0.001) but not in the MOGAD cohort (p = 0.262). Conclusions: The structural brain MRI features of MOGAD show higher global brain and WM volumes and lower brain volume loss over time compared to RRMS, suggesting different underlining pathogenetic mechanisms.<\/jats:p>","DOI":"10.3390\/jcm14072445","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T05:51:26Z","timestamp":1743659486000},"page":"2445","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brain Volume Measures in Adults with MOG-Antibody-Associated Disease: A Longitudinal Multicenter Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3375-4098","authenticated-orcid":false,"given":"Riccardo","family":"Orlandi","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Mariotto","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gobbin","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Rossi","sequence":"additional","affiliation":[{"name":"Neurology Unit, Mater Salutis Hospital, 37045 Legnago, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4925-9000","authenticated-orcid":false,"given":"Valentina","family":"Camera","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3362-7403","authenticated-orcid":false,"given":"Massimiliano","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Calabria","sequence":"additional","affiliation":[{"name":"Neurology Unit, Ospedale Borgo Trento, Azienda Ospedaliera Universitaria Integrata, 37126 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6539-0458","authenticated-orcid":false,"given":"Alberto","family":"Gajofatto","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102011","DOI":"10.1016\/j.msard.2020.102011","article-title":"Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: Two paradigmatic cases and a review of the literature","volume":"41","author":"Foiadelli","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","article-title":"Myelin oligodendrocyte glycoprotein: Deciphering a target in inflammatory demyelinating diseases","volume":"8","author":"Peschl","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"577260","DOI":"10.1016\/j.jneuroim.2020.577260","article-title":"Diagnostic features of initial demyelinating events associated with serum MOG-IgG","volume":"344","author":"Orlandi","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/jon.13137","article-title":"MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease","volume":"33","author":"Contentti","year":"2023","journal-title":"J. Neuroimaging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1212\/WNL.0000000000201465","article-title":"Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging","volume":"100","author":"Cortese","year":"2023","journal-title":"Neurology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0000000000003542","article-title":"Brain MRI atrophy quantification in MS","volume":"88","author":"Rocca","year":"2017","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nimg.2002.1040","article-title":"Accurate, robust, and automated longitudinal and cross-sectional brain change analysis","volume":"17","author":"Smith","year":"2002","journal-title":"NeuroImage"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.neuroimage.2004.07.051","article-title":"Advances in functional and structural MR image analysis and implementation as FSL","volume":"23","author":"Smith","year":"2004","journal-title":"NeuroImage"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","article-title":"User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability","volume":"31","author":"Yushkevich","year":"2006","journal-title":"NeuroImage"},{"key":"ref_13","first-page":"30","article-title":"volBrain: An Online MRI Brain Volumetry System","volume":"10","year":"2016","journal-title":"Front. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1867","DOI":"10.1212\/WNL.0000000000008479","article-title":"Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases","volume":"93","author":"Mariotto","year":"2019","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: A multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflamm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"Mader","year":"2011","journal-title":"Clin. Immunol."},{"key":"ref_19","first-page":"93","article-title":"Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis","volume":"87","author":"Stromillo","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1212\/WNL.0b013e3181e24136","article-title":"Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes","volume":"74","author":"Giorgio","year":"2010","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"118108","DOI":"10.1016\/j.jns.2021.118108","article-title":"Brain volume measures in adults with MOG-antibody associated disease: A longitudinal multicentre study","volume":"429","author":"Orlandi","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"104436","DOI":"10.1016\/j.msard.2022.104436","article-title":"Volumetric brain changes in MOGAD: A cross-sectional and longitudinal comparative analysis","volume":"69","author":"Lotan","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neurobiolaging.2019.05.010","article-title":"Lifespan normative data on rates of brain volume changes","volume":"81","author":"Battaglini","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00330-017-4921-x","article-title":"Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS","volume":"28","author":"Liu","year":"2017","journal-title":"Eur. Radiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: A UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: International recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2137833","DOI":"10.1001\/jamanetworkopen.2021.37833","article-title":"Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder","volume":"4","author":"Camera","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_30","first-page":"1","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102833","DOI":"10.1016\/j.msard.2021.102833","article-title":"NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders","volume":"50","author":"Mariotto","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"Guo","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_33","first-page":"e1858","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study","volume":"90","author":"Ruiz","year":"2018","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler. J."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zivadinov, R. (2016). Role of Neuroimaging in Multiple Sclerosis. Multiple Sclerosis, Academic Press.","DOI":"10.1016\/B978-0-12-800763-1.00018-X"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/jnnp-2016-314005","article-title":"Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease","volume":"88","author":"Tackley","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"499910","DOI":"10.3389\/fneur.2020.499910","article-title":"Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study","volume":"11","author":"Schmidt","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/13524585211018987","article-title":"Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis","volume":"28","author":"Messina","year":"2022","journal-title":"Mult. Scler. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/jnnp-2020-324826","article-title":"Brain structural alterations in MOG antibody diseases: A comparative study with AQP4 seropositive NMOSD and MS","volume":"92","author":"Duan","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2445\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:09:21Z","timestamp":1760029761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14072445"],"URL":"https:\/\/doi.org\/10.3390\/jcm14072445","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]}}}